Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.33 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19543007 | 0.82 | MEN1 (0.40) | THRATHRBMEN1KMT2A | |
| SCHEMBL9973392 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL27056796 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL26203820 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL18751717 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL9973396 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL26203818 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL25792722 | 0.82 | CES2 (0.35) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL22853821 | 0.82 | CES2 (0.35) | CES2MEN1KMT2AFAAHMAPK1 | |
| SCHEMBL9973391 | 0.82 | CES2 (0.48) | CES2MEN1KMT2AFAAHMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133985-B2 | Peptide nucleic acids conjugated with multi-amine linkers and nucleic acid detecting device using the same | PANAGENE INC. (KR) | 2012-03-13 | — | — | US | disclosed |
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | PANAGENE INC. (KR) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312197-A1 | PEPTIDE NUCLEIC ACIDS CONJUGATED WITH MULTI-AMINE LINKERS AND NUCLEIC ACID DETECTING DEVICE USING THE SAME | NPPA, PARN, PARG | THRA 461/4885THRB 1418/4885CES2 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.